A VISIONaerie™ approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, retinal diseases and other diseases of the eye
Press Release
Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2... Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105... Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™...STOCK Quote
NASDAQ: AERI
$39.17USD
Apr 18, 4:00 PM ET
VOLUME
623,975
DAY LOW/HIGH
$38.01/$40.24
52 - WEEK LOW/HIGH
$32.18/$74.75
